Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study
Today, GLP-1 agonists have largely replaced insulin as the preferred injectable option for Type 2 diabetes
This information helps clinicians determine whether symptoms are likely related to GLP-1 therapy, represent expected consequences of weight loss, or suggest an alternative diagnosis requiring specific investigation
Mouse anti-GAPDH antibody from Zhongshan Biotechnology (Beijing, China)
At JosephCareRX, we incorporate GLP-1-based medications as part of individualized treatment plans for patients struggling with obesity, type 2 diabetes, or metabolic syndrome
Between 2017-18 and 2022-23, the total prescription drug spending for Canadas public drug plans rose by more than $3 billion to a grand total of over $14 billion